EZH2 and epithelioid sarcoma: Among all EZH2 inhibitors (EZH2i), tazemetostat (EPZ6438) has been used for the treatment of epithelioid sarcomas that cannot be removed by surgery, becoming the first EZH2i approved by the US Food and Drug Administration (FDA) in 2020 (17, 18).